Which company develops and produces Tepotinib? Comprehensive analysis of drug information

Tepotinib is a targeted drug used to treat non-small cell lung cancer (NSCLC). It is developed and produced by Merck KGaA, Darmstadt, Germany, a well-known German pharmaceutical company. The drug is a highly selective MET tyrosine kinase inhibitor (TKI) specifically targeted at patients with locally advanced or metastatic NSCLC carrying MET exon 14 skipping mutations (METex14). Merck is a multinational pharmaceutical company with a long history, focusing on the development of innovative drugs in multiple fields such as tumors, immunity, and neurological diseases. Tepotinib is one of its important breakthroughs in the field of precision tumor treatment.

Tepotinib was first approved for marketing by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) in March 2020, becoming the world's first MET inhibitor approved for METex14-mutated NSCLC. Subsequently, the drug was successively approved by regulatory agencies in the United States, the European Union and other countries and regions, and officially entered the Chinese market in 2023, providing a new treatment option for domestic lung cancer patients. Tepotinib is sold under the trade name "Tepmetko" and is exclusively produced and sold by Merck in the international market.

In China, the introduction of tepotinib has been approved by the National Medical Products Administration (NMPA) and has been included in my country's medical insurance directory. It is suitable for patients with locally advanced or metastatic NSCLC diagnosed with METex14 skipping mutations. This allows domestic patients to obtain cutting-edge international targeted treatments more quickly and reduces the economic burden through medical insurance policies.

Merck is actively promoting the clinical research of tepotinib globally, and its pivotal clinical trialVISION study shows that the drug has good efficacy and safety in patients with METex14-mutated NSCLC. Research data shows that the objective response rate (ORR) of tepotinib reaches more than 40%, and the median progression-free survival (PFS) is significantly prolonged, providing an effective treatment option for patients with this type of lung cancer.

Reference materials:https://www.tepotinib.com/